Valaris (VAL)
(Real Time Quote from BATS)
$47.60 USD
-0.62 (-1.29%)
Updated Feb 5, 2025 10:44 AM ET
4-Sell of 5 4
B Value A Growth D Momentum A VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
VAL 47.60 -0.62(-1.29%)
Will VAL be a Portfolio Killer in February?
Zacks Investment Research is releasing its prediction for VAL based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for VAL
Biden's Offshore Drilling Ban: Impacts and Industry Outlook
VAL, PTEN, RIG: 3 Oil & Gas Drilling Stocks Holding Promise
VAL: What are Zacks experts saying now?
Zacks Private Portfolio Services
Valaris Limited (VAL) Misses Q3 Earnings Estimates
Diversified Energy's Gulf Coast Deal to Expand LNG Reach
Zacks.com featured highlights include KB Home, General Motors, The Greenbrier, JD.com and Barrick Gold
Other News for VAL
Valaris Ltd (VAL) Stock Price Up 3.12% on Feb 4
Condire Management, LP Acquires Significant Stake in Osisko Development Corp
Borr Drilling: My Conviction In This Investment Has Increased
Highwood Value Partners H2 2024 Letter To Investors
ValiRx Partners with Screenin3D for Advanced Cancer Research